Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.
OBJECTIVE
Persons with schizophrenia die earlier than the general population, in large part due to cardiovascular disease. The study objective was to examine effects of different antipsychotic treatments on estimates of 10-year coronary heart disease (CHD) risk calculated by the Framingham Heart Study formula.


METHODS
Change in 10-year risk for CHD was compared between treatment groups in 1125 patients followed for 18 months or until treatment discontinuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial.


RESULTS
The covariate-adjusted mean change in 10-year CHD risk differed significantly between treatments. Olanzapine was associated with a 0.5% (SE 0.3) increase and quetiapine, a 0.3% (SE 0.3) increase; whereas risk decreased in patients treated with perphenazine, -0.5% (SE 0.3), risperidone, -0.6% (SE 0.3), and ziprasidone -0.6% (SE 0.4). The difference in 10-year CHD risk between olanzapine and risperidone was statistically significant (p=0.004). Differences in estimated 10-year CHD risk between drugs were most marked in the tertile of subjects with a baseline CHD risk of at least 10%. Among individual CHD risk factors used in the Framingham formula, only total and HDL cholesterol levels differed between treatments.


CONCLUSIONS
These results indicate that the impact on 10-year CHD risk differs significantly between antipsychotic agents, with olanzapine producing the largest elevation in CHD risk of the agents studied in CATIE.
Daumit
Gail L
GL
Johns Hopkins Medical Institutions, Welch Center for Prevention, Epidemiology and Clinical Research, 2024 East Monument Street, Suite 2-500, Baltimore, MD 21287, United States. gdaumit@jhmi.edu
Goff
Donald C
DC
Meyer
Jonathan M
JM
Davis
Vicki G
VG
Nasrallah
Henry A
HA
McEvoy
Joseph P
JP
Rosenheck
Robert
R
Davis
Sonia M
SM
Hsiao
John K
JK
Stroup
T Scott
TS
Lieberman
Jeffrey A
JA
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D015897:Comorbidity; D003327:Coronary Disease / Q000139:chemically induced / Q000453:epidemiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D008137:Longitudinal Studies; D008297:Male; D009765:Obesity / Q000139:chemically induced / Q000453:epidemiology; D017063:Outcome Assessment, Health Care; D010352:Patient Dropouts; D018570:Risk Assessment; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology; D012565:Schizophrenic Psychology; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects
D014150:Antipsychotic Agents
N Engl J Med. 2005 Sep 22;353(12):1209-23
16172203
JAMA. 2007 Jul 18;298(3):299-308
17635890
J Nerv Ment Dis. 1972 Jan;154(1):31-42
4550211
Prev Cardiol. 2004 Fall;7(4):168-75
15539963
J Clin Psychiatry. 2002 Oct;63(10):856-65
12416594
J Nerv Ment Dis. 2006 Jun;194(6):404-10
16772856
J Clin Psychiatry. 1999 Apr;60(4):215-20
10221280
J Clin Psychopharmacol. 2003 Dec;23(6):595-600
14624190
Schizophr Res. 2000 Sep 29;45(1-2):21-8
10978869
Schizophr Res. 2004 Sep 1;70(1):1-17
15246458
Circulation. 1998 May 12;97(18):1837-47
9603539
J Nerv Ment Dis. 2005 Oct;193(10):641-6
16208158
J Clin Psychopharmacol. 2001 Aug;21(4):369-74
11476120
Schizophr Res. 2008 Apr;101(1-3):273-86
18258416
Schizophr Res. 2003 Mar 1;60(1):99-100
12505146
Br J Psychiatry. 1997 Dec;171:502-8
9519087
Psychiatr Serv. 1996 Dec;47(12):1356-63
9117475
Am J Psychiatry. 2004 Aug;161(8):1334-49
15285957
Prim Care Companion J Clin Psychiatry. 2006;8(6):329-33
17245453
Schizophr Bull. 2003;29(1):15-31
12908658
Br J Psychiatry. 2003 Dec;183:534-9
14645025
J Child Adolesc Psychopharmacol. 2001 Winter;11(4):415-24
11838824
Am J Psychiatry. 1992 Sep;149(9):1189-94
1503131
Diabetes Care. 2004 Feb;27(2):596-601
14747245
Schizophr Res. 2005 Dec 1;80(1):45-53
16198088
Int Rev Psychiatry. 2005 Jun;17(3):173-80
16194788
Am J Psychiatry. 1999 Nov;156(11):1686-96
10553730
Clin Pharmacol Ther. 1985 Jun;37(6):684-7
2860989
J Clin Psychiatry. 2001 May;62(5):347-9
11411816
J Nerv Ment Dis. 2003 Dec;191(12):799-805
14671456
Can J Psychiatry. 2006 Jul;51(8):480-91
16933585
Schizophr Res. 1992 Dec;8(2):93-102
1360812
Prev Chronic Dis. 2006 Apr;3(2):A42
16539783
Arch Intern Med. 1993 Jan 25;153(2):154-83
8422206
Schizophr Res. 2005 Dec 1;80(1):19-32
16137860
Schizophr Bull. 2003;29(2):393-7
14552512
J Clin Psychiatry. 2002 May;63(5):425-33
12019668
JAMA. 2001 Jul 11;286(2):180-7
11448281
Psychiatr Rehabil J. 2006 Spring;29(4):267-73
16689037